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http://dx.doi.org/10.1016/j.stemcr.2017.05.011SUMMARYAstrocyte dysfunction and neuroinflammation are detrimental features in multiple pathologies of the CNS. Therefore, the develop-
ment of methods that produce functional human astrocytes represents an advance in the study of neurological diseases. Here
we report an efficient method for inflammation-responsive astrocyte generation from induced pluripotent stem cells (iPSCs)
and embryonic stem cells. This protocol uses an intermediate glial progenitor stage and generates functional astrocytes that
show levels of glutamate uptake and calcium activation comparable with those observed in human primary astrocytes. Stimulation
of stem cell-derived astrocytes with interleukin-1b or tumor necrosis factor a elicits a strong and rapid pro-inflammatory response.
RNA-sequencing transcriptome profiling confirmed that similar gene expression changes occurred in iPSC-derived and primary
astrocytes upon stimulation with interleukin-1b. This protocol represents an important tool for modeling in-a-dish neuro-
logical diseases with an inflammatory component, allowing for the investigation of the role of diseased astrocytes in neuronal
degeneration.INTRODUCTION
Astrocytes are a major component of the human CNS. The
versatile and heterogeneous nature of astrocytes allows
them to perform multiple essential functions during
brain development and later in neuronal homeostasis
and synaptic transmission. Astrocytes are essential for
the establishment and plasticity of neural circuits since
they participate in the formation of synapses, in the
phagocytic removal of unwanted synapses, and in neuro-
transmitter recycling (Khakh and Sofroniew, 2015). Astro-
cytes are located close to blood vessels and participate in
the formation of the blood-brain barrier and in the regula-
tion of blood flow. They regulate extracellular ion concen-
trations and provide energy and substrates to neurons
(Sofroniew and Vinters, 2010). In addition to these sus-
taining functions, astrocytes participate in the response
to injury and disease by becoming reactive. Astrocyte reac-
tivity is a graded and complex response that includes
changes in morphology, gene expression, and inflamma-Stem Cel
This is an open access article under the Ction (Anderson et al., 2014; Colombo and Farina, 2016;
Pekny and Pekna, 2014; Sofroniew, 2009, 2015). Morpho-
logical changes range from hypertrophy and polarization
toward the site of injury to the formation of glial scars.
Genomic studies using two injury mouse models, ischemic
stroke and neuroinflammation, revealed extensive modifi-
cations in the transcriptome profiles of reactive astrocytes
with a common gene component and gene changes spe-
cific to each stimulus (Zamanian et al., 2012). As a result,
the role of astrocyte dysfunction and neuroinflammation
in multiple CNS pathologies is attracting attention (Pekny
et al., 2015).
During embryonic development, radial glial cells
generate progenitors that differentiate into neurons in
the early embryonic phase and into glial cells in the late
embryonic and postnatal periods. This switch from neuro-
genesis to gliogenesis involves epigenetic changes and
Notch signaling (Fan, 2005; Morrison et al., 2000; Taki-
zawa et al., 2001). Notch activates the JAK/STAT3 (Janus
kinase/signal transducer and activator of transcription 3)l Reports j Vol. 8 j 1757–1769 j June 6, 2017 j ª 2017 The Authors. 1757
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
pathway, which promotes astrogliogenesis (Kamakura
et al., 2004). In mice, astrocyte progenitors migrate radially
from the germinal ventricular zone and occupy a stable
territory throughout the life of the animal (Tsai et al.,
2012). Thus, morphological and functional astrocyte di-
versity is determined during development by the regional
patterning of the precursors (Hochstim et al., 2008; Tsai
et al., 2012). Data obtained from in vitro culture astrocytes
purified from human and rat brains showed that human
astrocytes occupy an extended territory and display a supe-
rior total arborization length (Zhang et al., 2016). Indeed,
significant differences exist between human and rodent as-
trocytes (Han et al., 2013; Oberheim et al., 2006, 2009;
Zhang et al., 2016) that may be relevant for functional
studies of astrocytes in the context of human neurological
disorders.
Future studies of human astrocyte response to inflamma-
tion require reliable in vitro models. Human astrocytes can
be cultured from fetal and adult biopsies; however, the
availability of CNS human tissue is reduced and immuno-
panning is required to obtain pure astrocyte preparations
(Zhang et al., 2016). The generation of astrocytes from
induced pluripotent stem cells (iPSCs) has the advantage
of obtaining access to astrocyte phenotypes and their ef-
fects on neuronal physiology from patients with neurode-
generative and neuropsychiatric diseases. However, the
development of efficient protocols to generate astrocytes
in a dish from stem cells is hindered by insufficient knowl-
edge of astrocyte specification during development and in
the adult CNS and by the lack of specific proteins expressed
by astrocytes that can be used as markers (Molofsky et al.,
2012). Recently, Zhang et al. (2016) identified human
astrocyte-specific genes and differences in transcription be-
tween astrocyte precursors and mature astrocytes. Current
available protocols focus on recapitulating the gliogenic
switch observed during embryonic development (Chan-
drasekaran et al., 2016; Emdad et al., 2012; Krencik and
Zhang, 2011; Roybon et al., 2013; Serio et al., 2013; Shal-
touki et al., 2013; Tyzack et al., 2016). Human iPSCs
(hiPSCs) or human embryonic stem cells (hESCs) are
converted into neural progenitor cells (NPCs) and then
patterned and switched to glial progenitor cells (GPCs)
that eventually differentiate and mature into astrocytes.
Recently, the conversion of mouse and human fibroblasts
into astrocytes using small-molecule induction has been
described (Tian et al., 2016). Despite the role that astrocytes
play in neuroinflammation, few studies have reported the
generation of pro-inflammatory astrocytes (Holmqvist
et al., 2015; Roybon et al., 2013). In this study, we describe
an efficient protocol to derive functional astrocytes from
glial progenitors that show a rapid inflammatory response
after stimulation with interleukin-1b (IL-1b) or tumor
necrosis factor a (TNF-a).1758 Stem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017RESULTS
Generation of Human Astrocytes from iPSCs and ESCs
through Differentiation of Intermediate GPCs
Existing protocols for differentiation of astrocytes from
human iPSCs or ESCs attempt to recapitulate embryonic
development by first generating NPC intermediates before
differentiating them into GPCs and finally into astrocytes
(Chandrasekaran et al., 2016; Tyzack et al., 2016). Current
methods are time consuming, and it is unclear whether the
derived astrocytes are inflammation responsive; hence we
sought to generate inflammation-responsive astrocytes in
a short period of time. We devised a method to efficiently
derive GPCs from PSCs, including iPSCs and ESCs, such
that they can be propagated, expanded, and frozen as inter-
mediates (Figure 1A). Free-floating embryoid bodies were
prepared from three iPSC cell lines and the hESC-H1 cell
line and cultured in Astrocyte medium (ScienCell) in the
presence of Noggin for 2 weeks for neural induction by
SMAD inhibition (Chambers et al., 2009). Platelet-derived
growth factor (PDGF) was added for 3 weeks to induce
the JAK/STAT pathway, which is necessary for astrogliosis
and oligodendrogenesis (Bonni et al., 1997; Fan, 2005;
Dell’Albani et al., 1998; He et al., 2005). The identity of
the GPCs was confirmed by the near ubiquitous expression
of Nestin and of A2B5 antigen, which is a cell surface
ganglioside known to be expressed in astrocyte precursors
(Figures 1B and 1C). In addition, the nuclear factor IA
(NFIA) is highly expressed in GPC (Figures 1B and 1C).
NFIA is a transcriptional factor downstream of Notch that
is necessary for the initiation of gliogenesis (Deneen
et al., 2006).
For the differentiation and maturation of astrocytes,
a neuronal medium with leukemia inhibitory factor
(LIF) and serum was used (Figure 1A). LIF also activates
the JAK/STAT signaling pathway (He et al., 2005). After
4–6 weeks of differentiation from the GPCs, we found
high expression of key astrocytic markers, such as CD44
antigen, S100b (S100 calcium-binding protein), and glial fi-
brillary acidic protein (GFAP), as for primary astrocytes (Fig-
ures 1B–1D). Although the expression of GFAP was almost
ubiquitous, the fluorescence levels detected were faint, sug-
gesting low expression, which was confirmed by western
blotting (Figure 1D). Expression of the aldehyde dehydro-
genase 1 family member L1 (ALDH1L1), an early marker
of astrocyte maturation, was also detected in a large per-
centage of primary astrocytes and ESC/iPSC-derived astro-
cytes but in a lower percentage of the population compared
with the other markers (Figures 1B and 1C). Maturing
astrocytes are known to express EAAT1 and EAAT2 (excit-
atory amino acid transporter 1/2), which are Na+-depen-
dent glutamate/aspartate transporters. Using western
blotting, we found that 4-week-old iPSC-derived astrocytes
Figure 1. Differentiation of Astrocytes
from Stem Cells via Glial Progenitor Cells
(A) Schematic representation of the exper-
imental paradigm used for differentiation
of human astrocytes over a total time of
6–8 weeks. Human iPSCs or ESCs were used
to generate floating embryoid bodies (EB),
followed by dissociated glial progenitor
cells (GPC), and were differentiated to as-
trocytes in monolayers (shown are repre-
sentative bright-field images for cells at
each stage). Scale bars, 20 mm.
(B) Representative fluorescent images of
immunostainings for ESC- and iPSC-derived
GPCs expressing Nestin (green), A2B5 (red),
or NFIA (green), and astrocytes (4-week
differentiation post GPC; 6-week differen-
tiation for GFAP) expressing ALDH1L1
(green), CD44 (green)/S100b (red), or GFAP
(green). All cells were counterstained for
DAPI (blue). Scale bars, 20 mm.
(C) Quantifications for percentage of cells,
GPCs, or astrocytes, positive for the listed
markers over DAPI. Results are expressed as
means ± SEM, n = 3 experiments for iPSC-
derived lines or n = 3 experiments for hESC-
derived lines and primary astrocytes.
(D) Representative western blots showing
expression of EAAT1, EAAT2, and GFAP
(4-week differentiation post GPC) in iPSC-
derived astrocytes or in cerebellar primary
astrocytes. GAPDH was used as a total pro-
tein loading control.
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Figure 2. Differentiated Astrocytes from
Human iPSCs and ESCs Are Functional
(A) Na+-dependent [3H]glutamate transport
in 6-week-old astrocytes differentiated from
iPSCs, ESCs, and human primary astrocytes is
similar. Neural progenitor cells (NPC) were
used as a negative control.
(B) Representative montages of Fluo-4
containing green astrocytes labeled as
distinct regions of interest (ROI) at different
time points (seconds). Scale bar, 20 mm.
(C) Twelve individual traces of calcium
transients (various colors) of astrocytes
represented as change in fluorescence/
minimum fluorescence (DF/Fmin) over time
(seconds).
(D) Graph shows percentage of the popula-
tion of astrocytes per video displaying cal-
cium transients in a period of 120 s.
(E) Graph depicts percentage of astrocytes
displaying calcium transients in different
treatment groups (with or without flufe-
namic acid).
Data are presented as mean ± SEM, n = 3
experiments. Statistical analysis by Mann-
Whitney test; *p < 0.05 (primary = 0.032;
iPSC1 = 0.012; iPSC2 = 0.004).expressed both EAAT1 and EAAT2 protein (Figure 1D).
Interestingly, we found higher protein levels of EAAT2
compared with EAAT1 in both iPSC-derived and primary
astrocytes. These results agreewith developmental observa-
tions that EAAT1 is expressed during development and
EAAT2 is expressed in the mature brain and accounts
for 90% of glutamate transport in astrocytes (Kim et al.,
2011). Remarkably, neuron differentiation from the GPCs
was never observed in astrocyte cultures immunostained
with anti-MAP2 antibody (Figure S1).
In summary, using the current protocol from hiPSCs, we
were able to efficiently generate GPCs and astrocytes, as
determined by the expression of key astrocytic markers
in vitro.
iPSC/ESC-Derived Astrocytes Actively Take Up
Glutamate and Display Calcium Transients
We next examined whether the generated astrocytes were
functionally mature. A hallmark of astrocyte function is1760 Stem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017glutamate uptake from the extracellular space (Robinson
and Jackson, 2016). Na+-dependent glutamate uptake
corresponds to the activity of EAAT1/2 transporters and
can be measured directly using a radioactive assay. We
observed that primary astrocytes and iPSC/ESC-derived
6-week-old astrocytes were able to take up glutamate at
comparable levels, suggesting the functional activity of
EAAT1/2 in the astrocytes in vitro (Figure 2A). This result
is in agreement with the expression of glutamate trans-
porters (Figure 1D).
Astrocytes are known to exhibit waves of calcium tran-
sients in a characteristic manner (Bazargani and Attwell,
2016; Rusakov, 2015; Shigetomi et al., 2016; Stout et al.,
2002). Using Fluo-4, a calcium-responsive dye, we exam-
ined calcium activity in the generated astrocytes.We found
that astrocytes displayed slow calcium transients over
a period of 2 min (Figures 2B and 2C; Movies S1, S2,
and S3), which are distinct from fast neuronal calcium
transients. Quantification of the percentage of astrocytes
displaying transients showed that approximately 25% of
the iPSC-derived astrocytes were active over a span of
2 min, similar to what was observed for primary human
cerebellar astrocytes (Figure 2D). Astrocytes are capable of
widespread intercellular communication, as observed by
propagated waves of calcium transients. These waves are
thought to be laterally propagated at least in part via gap
junctions. Therefore, we next examined whether 50 mM
flufenamic acid (flufen), a gap junction inhibitor, regulated
calcium transients in iPSC-derived astrocytes. iPSC-derived
astrocytes and primary astrocytes showedmore than a 50%
reduction in the percentage of cells displaying calcium
transients (Figure 2E and Movie S4), suggesting that func-
tional gap junctions enabled the propagation of calcium
waves in vitro.
Together, our data suggest that the iPSC-derived astro-
cytes not only expressed markers of maturing astrocytes
but also functionally took up glutamate, displayed typical
calcium transients, and showed functional gap junction-
regulated calcium activity in vitro.
Differentiated Astrocytes Respond to Pro-
inflammatory Stimuli
Astrocytes are immunocompetent cells that participate in
neuroinflammation by secreting cytokines and chemo-
kines, which may have protective or detrimental conse-
quences for neuronal survival (Colombo and Farina,
2016). Thus far, attempts to generate immunocompetent
human astrocytes have met with limited success. Two
studies using long protocols (between 13 and 18 weeks)
for differentiation of ventral midbrain and spinal cord
astrocytes reported the production of inflammatory cyto-
kines and chemokines by ELISA or protein arrays after stim-
ulation with IL-1b or TNF-a for 7 days (Holmqvist et al.,
2015; Roybon et al., 2013). However, using these assays it
is difficult to quantify the proportion of the cellular popu-
lation that becomes effectively reactive, which is an impor-
tant piece of information for functional assays.
Given the relevance of neuroinflammation in the
context of neurological diseases, we sought to examine
whether the astrocytes generated by our protocol were
immunocompetent. To test whether the astrocytes that
we generated produced cytokines upon pro-inflammatory
stimuli, we utilized a flow cytometry-based approach classi-
cally applied to immune cells (Jung et al., 1993; Picker et al.,
1995). In this assay, astrocytes were stimulated in the pres-
ence of monensin and brefeldin A, which disrupt the
Golgi-mediated protein transport, leading to an intracel-
lular accumulation of produced cytokines (Figure 3A).
Five hours post stimulation, astrocytes were fixed and per-
meabilized to enable the detection of intracellular IL-6 and
IL-8 cytokines using directly conjugated antibodies. Per-
centages of IL-6- and IL-8-producing astrocytes were quan-tified by flow cytometry (Figure 3B). In contrast to the
ELISA assay, which measures the total amount of cytokines
produced within a population of cells, this method allows
the quantification of the number of cytokine-producing
cells within a population. We observed high cell survival
rates (>90%) following treatmentwith protein transport in-
hibitors in both the non-stimulated and stimulated condi-
tions (Figure 3C) and no changes in cellular morphology
(Figure 3D). The production of IL-6 and IL-8 in all non-
stimulated samples was low (Figure 3E), indicating that
the inhibition of protein transport bymonensin and brefel-
din A did not promote the inflammatory response observed
in the IL-1b- or TNF-a-treated groups. To further validate
our assay, we pre-incubated ESC- and iPSC-derived astro-
cytes with an IL-1b receptor antagonist (IL-1RA) for 1 hr
before adding IL-1b (Figure S2). Blocking IL-1 receptor in
the presence of IL-1b drastically reduced the percentages
of IL-8- and IL-6-producing astrocytes, demonstrating
that the pro-inflammatory responsemeasured in astrocytes
was specific to the IL-1b stimulation.
Using this flow cytometry-based approach, we next
assessed the percentage of reactive primary astrocytes
and 4-week differentiated iPSC/ESC-derived astrocytes
following IL-1b or TNF-a pro-inflammatory treatment (Fig-
ures 3F and 3G). The response to IL-1b stimulation was
stronger than to TNF-a stimulation in all astrocytic
cell lines. Also, upon inflammatory stimulation a larger
percentage of astrocytes produced IL-8 (stem cell-derived
IL-1b-stimulated astrocytes: 71.4% ± 3.73%; TNF-a-stimu-
lated: 37.0% ± 2.24%) than IL-6 (stem cell-derived IL-1b-sti-
mulated astrocytes: 40.9% ± 3.71%; TNF-a-stimulated:
16.0% ± 2.70%). Despite inter-donor variability, iPSC-
derived astrocytes were found to be robustly reactive at
levels comparable with primary and ESC-derived astro-
cytes. These results suggest that, similar to primary
astrocytes, iPSC-derived human astrocytes are immuno-
competent as they not only responded to inflammatory
stimuli but could also further sustain inflammation by pro-
ducing pro-inflammatory cytokines themselves.
Transcriptomic Analysis of IL-1b-Stimulated
Astrocytes
To examine the transcriptomic inflammatory signature
in response to pro-inflammatory cytokines, we performed
RNA sequencing (RNA-seq) analysis of IL-1b-stimulated
iPSC-derived astrocytes in the absence of monensin
and brefeldin A. Unsupervised hierarchical clustering of
IL-1b-stimulated astrocytes derived from three iPSC lines,
in duplicates, revealed that stimulated and non-stimulated
astrocytes clustered separately (Figure 4A). Similarly, stimu-
lated andnon-stimulated iPSC-derived astrocytes separated
out distinctly in principal component analysis, suggesting
that the transcriptional signature of stimulated astrocytesStem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017 1761
Figure 3. Pro-inflammatory Cytokine Production in Response to Inflammatory Stimulation Is Comparable between iPSC-Derived
Astrocytes and Primary Astrocytes
(A) Experimental paradigm used to assess pro-inflammatory cytokine production at a single-cell level in astrocyte cultures. Primary, ESC-
derived, or iPSC-derived astrocytes were stimulated with IL-1b (10 ng/mL) or TNF-a (50 ng/mL), or left in medium with vehicle. Protein
transport inhibitors were added to the cultures to block the release of produced cytokines. Five hours later, cells were stained intracel-
lularly with antibodies against IL-8 and IL-6. The percentage of cytokine-producing cells was then analyzed by flow cytometry.
(B) Representative FACS plots showing percentages of IL-8-positive (top) and IL-6-positive (bottom) primary cerebellar astrocytes 5 hr
after stimulation with media + vehicle (Non-stimulated), IL-1b, or TNF-a, in the presence of protein transport inhibitors.
(C) Bar graphs showing the percentages of live astrocytes (negative for the viability dye Zombie UV), 5 hr after incubation with medium +
vehicle (Non-stimulated), IL-1b, or TNF-a, in the presence of protein transport inhibitors (mean ± SD, n = 3 experiments).
(D) Representative bright-field images of iPSC-derived astrocytes 5 hr after incubation with (left) medium + vehicle (Non-stimulated) or
(right) IL-1b, in the presence of protein transport inhibitors. Scale bar, 20 mm.
(E–G) Histograms showing the percentages of IL-8-positive (blue) and IL-6-positive (red) astrocytes of indicated primary or stem cell-
derived cultures, 5 hr after incubation with (E) medium + vehicle (Non-stimulated), (F) IL-1b, or (G) TNF-a, in the presence of protein
transport inhibitors (mean ± SD, n = 3 experiments). Background activation obtained in the non-stimulated condition was subtracted from
stimulated conditions (mean ± SEM, n = 3 experiments).
1762 Stem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017
Figure 4. Transcriptomic Analysis of IL-1b-Stimulated Astrocytes
Whole transcriptomic analysis was performed on stimulated and non-stimulated primary astrocytes, iPSC-derived astrocytes, and neural
progenitor cells (NPC).
(A) Unsupervised hierarchical clustering of the whole transcriptome of non-stimulated and IL-1b-stimulated iPSC-derived astrocytes and
of iPSC-derived astrocytes. Replicates are referred as ‘‘a’’ and ‘‘b.’’
(B) Principal component (PC) analysis of IL-1b-stimulated astrocytes shows distinct clustering of activated and non-activated iPSC-
derived astrocytes, iPSC-derived NPCs, and primary astrocytes.
(C) Venn diagram depicts overlapping set of significantly upregulated genes following IL-1b stimulation between primary astrocytes and
iPSC-derived astrocytes, with percentage of overlapping genes shown.
(D) Table shows gene ontology (GO) analysis for all genes significantly upregulated in stimulated versus non-stimulated iPSC-derived
astrocytes. Listed are GO terms, fold enrichment of genes in each category, and false discovery rate (FDR) corrected p values for each GO
term.represents an acutely distinct state (Figure 4B). To further
confirm the specificity of the inflammatory signature of
iPSC-derived astrocytes, we compared the whole transcrip-
tome of stimulated and non-stimulated samples with NPCs
derived from the same iPSC lines and with primary astro-
cytes. The NPCs were used as negative controls since they
did not show a significant production of pro-inflammatory
cytokines (IL-6 and IL-8) upon IL-1b stimulation (Fig-
ure S3). To understand the nature of the genes upregulated
following IL-1b stimulation, we compared the sets of genes
upregulated in primary astrocytes with iPSC-derived astro-
cytes (Figure 4C). A total of 776 and 435 genes were signif-
icantly upregulated in stimulated primary astrocytes andiPSC-derived astrocytes, respectively. We found that 331
genes were common between these lists (Table S1), which
accounted for more than 76% of genes upregulated in
iPSC-derived astrocytes and 42% of genes upregulated in
primary astrocytes, showing a substantial overlap in the
pathways upregulated in primary and iPSC-derived astro-
cytes following IL-1b stimulation (Figure 4C). To further
characterize the upregulated pathways in an unbiased
manner, we performed gene ontology (GO) analysis of all
significantly upregulated genes in iPSC-derived astrocytes.
We filtered GO categories on the basis of highest signifi-
cance corrected for false discovery rate and found a 2- to
16-fold enrichment for inflammation-related GO termsStem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017 1763
Figure 5. Astrocytes Differentiated from iPSCs Behave in a Similar Fashion to Primary Astrocytes in Co-cultures with Neurons
(A) Experimental paradigm of the co-culture experiment. FACS-sorted 4-week-old neurons were plated on top of astrocytes differentiated
for 4 weeks from GPCs stimulated or not with IL-1b for 5 hr. Neuronal survival and morphological maturation (neurite length) was assayed
following 48 hr of co-culture.
(B) Representative confocal images of immunostainings of synapsin-GFP-expressing neurons after co-culture with astrocytes. Scale bars,
20 mm.
(C) iPSC-derived astrocytes can support neuronal survival. Treatment of astrocytes with pro-inflammatory cytokine IL-1b affects neuronal
survival similarly in co-cultures with primary or iPSC-derived astrocytes.
(D) Maturation of neurons measured by dendritic length is similar in primary and iPSC-derived astrocytes but is affected by IL-1b pre-
treatment on astrocytes.
Statistical analysis on independent triplicates: two-way ANOVA following outlier removal, *p < 0.01 (p = 0.006; n = 3 for C and n = 15
neurons per line from independent triplicates for D). Results are expressed as means ± SEM.such as inflammatory response, immune response, chemo-
kine activity, and cytokine activity (Figure 4D).
Inflammatory Stimulation of iPSC-Derived Astrocytes
Affects Neuron Viability and Morphology
To study the functional consequences of pro-inflammatory
astrocytes on neurons, we used an in vitro co-culture assay
in which synapsin-positive neurons were isolated by fluo-
rescence-activated cell sorting (FACS) and plated on top
of 4-week-old astrocytes that had been previously treated
with vehicle or stimulated with IL-1b for 24 hr (Figure 5A).
Sorted neurons were co-cultured with astrocytes for 48 hr
in the absence of cytokines. Following fixation, neuronal
survival and neurite outgrowth were assayed for co-cul-
tures with iPSC/ESC-derived and primary astrocytes. We
observed that a significantly lower percentage of neurons
co-cultured with IL-1b pre-treated astrocytes compared
with vehicle pre-treated astrocytes (Figure 5B). Similarly,
we observed a drastic reduction in the dendritic length of1764 Stem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017neurons co-cultured with astrocytes pre-treated with
IL-1b (Figures 5C and 5D). These data suggest that stimula-
tion of inflammatory response in iPSC-derived astrocytes
directly affects neuronal viability and morphology. The
results of these experiments indicate that stimulated
astrocytes have a sustained and direct impact on neuronal
maturation and survival even after a washout of the
pro-inflammatory cytokines, suggesting that the protocol
described here can be used for modeling neurological dis-
eases with an inflammatory component.DISCUSSION
Alongwithmicroglia and other non-neural cells, astrocytes
participate in the inflammatory response of the CNS to
injury and disease by producing cytokines, chemokines,
pro-oxidant molecules, and signaling factors (DiSabato
et al., 2016; Sofroniew, 2015). Astrocytes also play an
important role inmaintaining brain function homeostasis,
and their dysfunction can trigger progression of neurode-
generative diseases (Chandrasekaran et al., 2016). Much
of our current knowledge on astrocyte biology comes
from the study of rodents. Recently it was shown that
human astrocytes are intrinsically more complex than
mouse astrocytes, and astrocytes express unique genes
and respond differently to extracellular glutamate (Han
et al., 2013; Oberheim et al., 2006, 2009; Zhang et al.,
2016). Importantly, drugs that showed promising results
in animal models have failed in human trials (Cavanaugh,
2014; Cummings et al., 2014; Rothstein, 2003; Waldmeier
et al., 2006), possibly due to the different properties of hu-
man astrocytes. Therefore, the development of applicable
and relevant human models for studying neurological dis-
ease mechanisms and testing drugs has become necessary.
Here we report an efficient method for differentiating
inflammation-responsive astrocytes from human iPSCs
and ESCs.
A major breakthrough in the study of astrocytes was the
description of a procedure to purify and culture astrocytes
from neonatal rodent brains using serum-containing me-
dia (McCarthy and de Vellis, 1980). This protocol was
used and modified for decades to culture not only rodent
cells but also human astrocytes from fetal postmortem tis-
sue (Ennas et al., 1992; Lee et al., 1993). Recently, new
methods of astrocyte purification using immunopanning
combined with serum-free culture have been described
for adult rodent and human brains (Foo et al., 2011; Zhang
et al., 2016). These methods are attractive because the
selected astrocytes are functional and are expected to be
more similar to their in vivo equivalents. However, these
are invasive techniques; for example, the temporal lobe
cortex tissue used by Zhang et al. (2016) was excised during
surgery to expose the epileptic hippocampi, and the broad
application of this technique to the study of human neuro-
logical disorders remains challenging. In addition, most
neuroinflammatory, neurodegenerative, and psychiatric
conditions aremultigenic and poorly described genetically.
Thus, cellular models that rely on the differentiation of as-
trocytes from iPSCs or other non-brain cell types are still
the most accessible methods for in vitro disease modeling
and can potentially allow for new discoveries. Indeed,
astrocyte dysfunction was found in Costello and Down
syndromes using iPSC-derived astrocytes uncovering new
drug targets (Chen et al., 2014; Krencik et al., 2015).
Inflammation is one of the main features of neurodegen-
erative diseases (Campbell, 2004). Having methods avail-
able that generate human astrocytes that are responsive to
inflammation allows for the modeling of this component
of the disease using patients’ cells. Previous studies reported
the generation of reactive astrocytes after a 7-day treatment
with IL-1b or TNF-a (Holmqvist et al., 2015; Roybon et al.,2013), but, as the authors used the ELISA assay or protein ar-
rays to quantify chemokine and cytokine production, it is
difficult to assesswhat proportionof the cellular population
became effectively reactive. In our hands, classical proto-
cols using iPSC-derived NPCs (Chandrasekaran et al.,
2016; Tyzack et al., 2016) did not generate astrocytes
responsive to pro-inflammatory stimuli using the FACS-
based assaydescribed in this study.Herewe report amethod
for differentiating astrocytes using intermediate GPCs that
were generated in a serum-containingmedium that is remi-
niscent of theMcCarthy-deVellis astrocyte culture protocol
(McCarthy and de Vellis, 1980). Because astrocytes contact
blood vessels in vivo, it is possible that the serum contains
unknown signals necessary for the differentiation of astro-
cytes responsive to inflammatory stimuli in culture.
The protocol presented here represents a robust tool
for modeling neurological diseases with an inflammatory
component, for example Parkinson’s disease and Alz-
heimer’s disease. It allows for investigating the role of
diseased astrocytes in neurodegenerative disease and the
possibility of screening new anti-inflammatory drugs. In
addition, this protocol can also be used to explore the
cell-autonomous role of astrocytes and inflammation in
other disorders including certain psychiatric disorders.EXPERIMENTAL PROCEDURES
Differentiation of Astrocytes from Human iPSCs
and ESCs
The human iPSC lines used in this study were Sendai-reprog-
rammed from fibroblasts and correspond to control cell lines
(NM1–4; here named as hiPSC1–4 for simplicity), as described by
Mertens et al. (2015). All subjects provided written informed con-
sent and all procedures were approved by local human subjects
committees. iPSC and hESC H1 (WiCell Research Institute) lines
were cultured on Matrigel-coated plates in mTeSR1 medium
(STEMCELL Technologies). Embryoid bodies were prepared
from confluent stem cell cultures by mechanical dissociation
with 1 mg/mL collagenase IV (Invitrogen), plated onto low-adher-
ence plates in mTeSR1 medium with 10 mM ROCK inhibitor
(Axxora), and incubated overnight with agitation. For differentia-
tion of GPC in the embryoid bodies, Astrocyte medium (AM,
ScienCell) supplemented with 500 ng/mL Noggin (Peprotech)
and 10 ng/mL PDGFAA (R&D Systems) was used for 14 days and
then, for 1 more week, supplemented only with PDGFAA. The
embryoid bodieswere dissociatedwith papain (Papain dissociation
system, Worthington), and the GPC were cultured and expanded
in 10 mg/mL poly-L-ornithine (Sigma)/1 mg/mL laminin (Invitro-
gen)-coated plates in AM supplemented with 20 ng/mL fibroblast
growth factor 2 (Joint Protein Central) and 20 ng/mL epidermal
growth factor (Peprotech). Astrocytes were differentiated from
low-confluent GPC cultures in DMEM/F12 Glutamax (Thermo
Fisher Scientific) supplemented with N2 and B27 (both from
Thermo Fisher Scientific) and 10% fetal bovine serum (FBS, OmegaStem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017 1765
Scientific). Human LIF (10 ng/mL, Alomone Labs) was added for
the first 2 weeks of differentiation. After 2 weeks of differentiation,
the cells were transferred to non-coated plates. The human fetal
primary astrocytes fromcerebellumwere purchased fromScienCell
and cultured in AM. The NPC cell lines used in this study were
derived from the same iPSC lines and cultured using previously
described protocols (Mertens et al., 2015; Yu et al., 2014).
Immunocytochemistry
The cells plated on plastic slides were fixed with 4% paraformalde-
hyde solution for 15 min at room temperature. Antigen blocking
and cell permeabilization were done using 10% horse serum
and 0.1% Triton X-100 in PBS for 1 hr at room temperature. Pri-
mary antibodies were incubated in 10% horse serum overnight
at 4C, and the secondary antibodies (1:250, Jackson Laboratories)
were incubated in the same solution for 1 hr at room temperature.
The cells were counterstained with DAPI for detection of nuclei.
The following primary antibodies were used: mouse anti-Nestin
(1:500; EMD Millipore), rabbit anti-S100b (1:1,000; Dako), mouse
anti-GFAP monoclonal (1:250; EMD Millipore), rat anti-CD44
(1:100; BD Pharmingen), rabbit anti-NFIA (1:250; Novus Bio),
mouse anti-ALDH1L1 (1:100; EMD Millipore), mouse immuno-
globulinM (IgM) anti-A2B5 (1:50; EMDMillipore). For A2B5 detec-
tion in live unfixed cells, the cells were incubated with anti-A2B5
antibody in DMEM/F12 Glutamax medium at 37C for 40 min.
After washing in warm PBS, fixation and secondary antibody
application were performed as described above.
Flow Cytometry Assay for Cytokine Stimulation
Astrocytes differentiated for 4weeks andprimaryhumanastrocytes
were incubated for 5 hr with protein transport inhibitors (1:1,000;
BDGolgiPlug, BDGolgiStop; BDBiosciences) and10ng/mL recom-
binant human IL-1b (R&D) or with 50 ng/mL recombinant human
TNF-a (R&D) or PBS (vehicle) for the non-stimulated sample. For
IL-1b receptor antagonist (IL-1RA) experiments, astrocytes were
pre-incubated with carrier-free recombinant human IL-1RA (Bio-
legend) at 10 ng/mL for 1 hr prior to 5 hr of stimulation with
10ng/mL IL-1b, 10ng/mL IL-1RA, andprotein transport inhibitors.
After stimulation, the cells were dissociated for 1min at room tem-
perature in a mixture of 1:1 Accutase (STEMCELL)/papain (Papain
dissociation system, Worthington), and washed and stained with
the viability dye Zombie UV fixable kit (Biolegend). Cells were
then fixed and permeabilized using the BD Cytofix/Cytoperm
and BD Perm/Wash (BD Biosciences). The IL-6 and IL-8 cytokines
were detected after incubation for 20 min at 4C in BD Perm/
Wash containing PerCP conjugated anti-IL-8 (BH0814) and APC
conjugated anti-IL-6 (MQ213A5) antibodies (Biolegend). Data
from labeled samples were acquired using a BD CantoII cytometer
(BD Biosciences) followed by analysis using FlowJo software
(TreeStar). Stainings with rat IgG1-APC (Biolegend, RTK2071) and
mouse IgG2b-PercP (Biolegend, MPC-11) were used for negative
gating controls for anti-IL-6 and anti-IL-8, respectively. Negative
gates were defined using unstimulated conditions.
Calcium Imaging
5- to 7-week-old astrocyte cultures were loaded with the calcium-
sensitive dye Fluo-4. Fluo-4 was prepared according the manufac-1766 Stem Cell Reports j Vol. 8 j 1757–1769 j June 6, 2017turer’s instructions from an imaging kit (Life Technologies) and
directly added to culture medium. Astrocyte cultures were incu-
bated with 1 mM Fluo-4 for 15 min at 37C. Cells were washed
with medium once and imaged immediately. Live fluorescent
imaging was performed using a Zeiss spinning-disk confocal mi-
croscope, using a standard fluorescein isothiocyanate filter, and
images were taken every 131 ms with the 203 objective for
120 s. Five areas with visibly spread astrocytes were selected for im-
aging for each line, and experimentswere repeated three times. For
quantification of change in intensity over time, astrocytes were
outlined as regions of interest (ROI) and analyzed using ImageJ
software. For each ROI, change in fluorescence intensity over
time (DF) was plotted. Values were normalized to the minimum
fluorescence (Fmin) value for each individual ROI and representa-
tive traces are presented as DF/Fmin over time. The percentage of
cells activated was counted manually by an observer blinded to
the groups, counting howmany ROIs in each video displayed tran-
sients (examples of traces shown in Figure 2) comparedwith the to-
tal number of visible ROIs.RNA-Seq Library Construction and Sequencing
RNA-seq analysis was performed in non-stimulated astrocytes and
4-week-old astrocytes stimulated for 5 hr with 10 ng/mL IL-1b
(without protein transport inhibitors) and NPCs derived from
the same iPSC lines. Details of the method are provided in Supple-
mental Experimental Procedures.Astrocyte-Neuron Co-cultures
For the co-culture experiments, GPC were plated at 1 3 105 cells
per well on 4-well chamber slides and further differentiated for
4 weeks into astrocytes (see scheme in Figure 4A). The astrocytes
were then activated with cytokine IL-1b on day 28 of differentia-
tion for 5 hr and washed with PBS to remove the residual cytokine
before the addition of sorted neurons. For the neuronal co-cul-
tures, 4-week-old neurons (cell line WT126, iPSC [Marchetto
et al., 2010]) infected with a lentiviral vector expressing GFP under
the control of synapsin promoter (Lenti-Syn:GFP) were sorted
by FACS. Sorted neurons were plated on top of the astrocytes
(20,000 neurons per well of a 4-well chamber slide) in neuronal in-
ductionmedium (DMEM/F12 with N2, B27, 2% FBS, and laminin)
without the addition of IL-1b. The neurons were co-cultured with
the astrocytes for the following 48 hr. The co-cultures were then
fixed with 4% paraformaldehyde and immunocytochemistry per-
formed with GFP (1:500 chicken anti-GFP; Aves Labs) for quantifi-
cation of the percentage of survival and the neurite length.
Neuronal survival was calculated by counting the number of
GFP-positive neurons 48 hr after co-culture and comparing this
with the total number of cells plated. In brief, we counted the num-
ber of cells that attached in the well and divided it by the number
ofGFP neurons plated following the cell sorting.We performed the
experiment in triplicate. For the neurite outgrowth assays, images
were processed using ZEN Imaging software (Carl Zeiss Micro-
scopy). Neurolucida (MBF Bioscience 11) was used to reconstruct
individual GFP-labeled neurons after co-culture, and to perform
subsequent morphological analyses along with Mirosoft Excel.
A total of 15–20 neurons per astrocyte line for each treatment
(IL-1b or vehicle) were analyzed.
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Supplemental Figure S1.  
GPC differentiate into astrocytes but not neurons. Shown are representative fluorescence 
images of immunostainings of MAP2ab (green) and GFAP (red) of astrocytic cultures 
differentiated 6 weeks post-GPC that were counterstained for DAPI (blue). The arrowheads point 
to GFAP-positive cells. Scale bar: 20 µm. Related to Figure 1.  
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Supplemental Figure S2.  
Pro-inflammatory cytokine production is specific to IL-1β stimulation. ESC-derived and 5-
week old iPSC-derived astrocytes (hiPSC_1) were pre-incubated in the absence (-) or presence of 
(+) IL-1β receptor antagonist (IL-1RA) for 1 h prior to 5 h incubation in media + vehicle  (non-
stimulated) or IL-1β, in the presence of protein transport inhibitors. Statistical analysis performed 
on independent triplicates- T-test *** p < 0.001, ** p < 0.01 (mean ± SD, n=3). Related to Figure 
3. 
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Supplemental Figure S3. Neural progenitor cells do not respond to inflammatory 
stimulation. Histograms showing the percentages of IL-8- (blue) and IL-6- (red) positive 
NPC  derived from 2 iPSC lines, 5 h after incubation with IL-1β in the presence of protein 
transport inhibitors. Background activation obtained in the non-stimulated condition was 
subtracted from stimulated conditions  (mean ± SD, n=3-9, T-test *** p < 0.001). Statistical 
analysis performed on independent triplicates. Related to Figure 4. 
 
SUPPLEMENTAL VIDEOS 
Video S1. Video showing calcium transients for hiPSC_1-derived astrocytes stained with fluo-4. 
Related to Figure 2. 
Video S2. Video showing calcium transients for hiPSC_3-derived astrocytes stained with fluo-4. 
Related to Figure 2. 
Video S3. Video showing calcium transients for cerebellar primary astrocytes stained with fluo-4. 
Related to Figure 2. 
Video S4. Video showing calcium transients for hiPSC_1-derived astrocytes stained with fluo-4 
and treated with 50 µM flufenamic acid. Related to Figure 2. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Western Blotting 
For Western blotting, cells were scraped from the dishes in RIPA buffer (Thermo Scientific) 
containing protease and phosphatase inhibitors (Thermo Scientific) and incubated for 5 min on 
ice. Lysates were clarified by centrifugation (14,000 xg for 15 min at 4°C) and Western 
immunoblotting was performed following standard procedures using the iBlot gel and transfer 
system (Life Technologies). Primary antibodies for mouse anti-EAAT1 (1:1,000; Santa Cruz), 
mouse anti-EAAT2 (1:1,000; Santa Cruz), rabbit anti-GFAP polyclonal (1:5,000; ThermoFisher 
Scientific), and mouse anti-GAPDH (1:5,000; Fitzgerald Industries International) were incubated 
sequentially (overnight at 4°C). Anti-mouse (1:5,000) horseradish peroxidase-coupled secondary 
antibodies were added (1 h at room temperature) and detected sequentially using ECL 
luminescence solution (Millipore) as per the manufacturer’s instructions. 
 
Glutamate Uptake 
Glutamate uptake assay was performed according to Gupta et al. (2011). Astrocytes differentiated 
for 6 weeks were washed in warm Na+-containing Krebs buffer (120 mM NaCl, 25 mM NaHCO3, 
5 mM KCl, 2 mM CaCl2, 1 mM KH2PO4, 1 mM MgSO4, 10% glucose) and then incubated in the 
same buffer containing 50 µM glutamate and 1 µCi 3H-glutamic acid (47.5 Ci/nmol; 
PerkinElmer). The same procedure was performed with Na+-free Krebs buffer (120 mM choline-
Cl, 25 mM Tris-HCl pH 7.4, 5 mM KCl, 2 mM CaCl2, 1 mM KH2PO4, 1 mM MgSO4, 10% 
glucose). The cells were lysed in 0.1 N NaOH and the radioactivity was measured using a 
LS6500 (Beckman) scintillation counter. The Na+-dependent glutamate uptake was calculated by 
subtracting the counts in Na+-free buffer to the counts in Na+-containing buffer. 
 
RNA-seq Library Construction and Sequencing 
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Non-stimulated and 5-h 10 ng/ml IL-1β-stimulated 4-week-old astrocytes (without protein 
transport inhibitors) were collected in RNABee solution (Tel-test, Inc) and total RNA was 
extracted using DNA-Free RNA Kit (Zymo Research) according to the manufacturer’s 
instructions. RNA quality was assayed using Agilent Technologies 2200 TapeStation and 
samples with integrity superior to RIN 7 were used for library preparation. Stranded mRNA-Seq 
libraries were prepared using the Illumina TruSeq Stranded mRNA Library Prep Kit according to 
the manufacturer’s instructions. Briefly, RNA with poly-A tail was isolated using magnetic beads 
conjugated to poly-T oligos. mRNA was then fragmented and reverse-transcribed into cDNA. 
dUTPs were incorporated, followed by second strand cDNA synthesis. dUTP-incorporated 
second strand was not amplified. cDNA was then end-repaired, index adapter-ligated and PCR 
amplified. AMPure XP beads (Beckman Coulter) were used to purify nucleic acid after each step 
of the library prep. All sequencing libraries were then quantified, pooled and sequenced at single-
end 50 base-pair (bp) on Illumina HiSeq 2500 at the Salk Institute Next Generation Sequencing 
(NGS) Core. Raw sequencing data were demultiplexed and converted into FASTQ files using 
CASAVA (v1.8.2). 
Sequenced reads were quality-tested using FASTQC (Andrews, 2010; available online at 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and aligned to the hg19 human 
genome using the STAR aligner (Dobin et al., 2013) version 2.4.0k. Mapping was carried out 
using default parameters (up to 10 mismatches per read and up to 9 multi-mapping locations per 
read).  Raw gene expression was quantified across all gene exons (RNA-Seq) using the top-
expressed isoform as proxy for gene expression, and differential gene expression was carried out 
using the edgeR (Robinson et al., 2010) package version 3.6.8 using replicates to compute 
within-group dispersion. P-values were adjusted to control the false discovery rate (FDR) by the 
method of Benjamini and Hochberg (Benjamin and Hochberg, 1995). Differentially expressed 
genes were defined as having a FDR <0.05 and a log2 fold change >1. Hierarchical clustering 
was performed using the R 3.3.2 software language. The heat map represents the normalized 
expression of the top expressed genes. Color represents expression from low (white) to high 
(blue). Principal component analysis was performed using the R 3.3.2 language. Normalized 
counts were processed using R 3.3.2 software to generate visual graphics for each group. We 
used DAVID (http://david.abcc.ncifcrf.gov/) to perform the functional GO (Gene Ontology) 
annotation analyses.   
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Antibody information 
mouse anti-EAAT1 (1:1,000; Santa Cruz, sc-15316) 
mouse anti-EAAT2 (1:1,000; Santa Cruz, sc-365634) 
rabbit anti-GFAP polyclonal (1:5,000; ThermoFisher Scientific, 01670276) 
 mouse anti-GAPDH (1:5,000; Fitzgerald Industries International, NC9864008)  
 mouse anti-nestin (1:500; EMD Millipore, MAB5326MI) 
 rabbit anti-S100β (1:1,000; Dako, Z031129-2) 
mouse anti-GFAP monoclonal (1:250; EMD Millipore, MAB360MI) 
 rat anti-CD44 (1:100; BD Pharmingen, BDB550538) 
rabbit anti-NFIA (1:250; Novus Bio, NBP181406) 
mouse anti-ALDH1L1 (1:100; EMD Millipore, MABN495) 
mouse IgM anti-A2B5 (1:50; EMD Millipore, MAB312) 
donkey anti-mouse HRP (1:5000, GE Healthcare Life Sciences, NA931) 
donkey anti-mouse IgG alexa488/cy3/cy5 (1:250, Jackson ImmunoResearch, 715-545-151/ 715-165-151/ 715-175-
151) 
donkey anti-rabbit HRP (1:5000, GE Healthcare Life Sciences,	NA934) 
donkey anti-rabbit IgG alexa488/cy3/cy5 (1:250, Jackson ImmunoResearch, 711-545-152/ 711-165-152/ 711-175-
152) 
 
 
 
